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Almost 2 billion people lack access to essential 
medicines.1 This deprivation causes immense and
avoidable suffering: ill health, pain, fear, loss of 
dignity and life. 2 Improving access to existing 
medicines could save 10 million lives each year, 
4 million of them in Africa and South-East Asia. 3
Besides deprivation, gross inequity in access to 
medicines remains the overriding feature of the
world pharmaceutical situation. 4 Average per capita
spending on medicines in high income countries is
100 times higher than in low-income countries:
about US$400 compared with US$4. The World
Health Organisation (WHO) estimates that 15 per
cent of the world’s population consumes over 90 per
cent of the world’s production of pharmaceuticals. 5
National and international policies, rules and 
institutions give rise to these massive deprivations
and inequalities. National supply systems for 
medicines often do not reach those living in poverty.
If they do, the medicines are often unaffordable.
Historically, research and development has not
addressed the priority health needs of those living 
in poverty. Alternative arrangements are feasible 
and reforms are urgently required. Indeed, they are
demanded by legal and ethical duties, including
those arising from international human rights law. 
Millennium Development Goals (MDGs), including
those connected to sexual and reproductive health
such as reducing child mortality, improving maternal
health, and combating HIV/AIDS, malaria and other
diseases, depend upon improving access to medi-
cines. Indeed, one of the MDG targets is to provide,
“in cooperation with pharmaceutical companies,
access to affordable essential drugs in developing
countries.” 6 Crucially, implementation of the right 
to the highest attainable standard of health can 
help to achieve the sexual and reproductive health-
related Goals.
Medical care in the event of sickness, as well as
the prevention, treatment and control of diseases,
are central features of the right of everyone to the
enjoyment of the highest attainable standard of
physical and health (in short, the “right to the 
highest attainable standard of health” or “right 
to health”). 7
These features depend upon access to medicines.
Thus, access to medicines forms an indispensable
part of the right to the highest attainable standard
of health. Numerous court cases, as well as 
resolutions of the United Nations (UN) Commission
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on Human Rights, confirm 
that access to essential medi-
cines is a fundamental element
of the right to health. 8 Some 
of the cases also confirm that
access to essential medicines
issues are closely connected to
other human rights, such as the
right to life.
In 2002, the Commission 
on Human Rights, which was at
that time the principal political
body dealing specifically with
human rights in the UN system,
decided to appoint a Special
Rapporteur to focus on the right
of everyone to the enjoyment of
the highest attainable standard
of physical and mental health. 
A Special Rapporteur is an 
independent expert appointed 
to monitor, examine and report
on either a particular human
rights issue or the human rights
situation in a particular country
or territory. 
In 2002, the Commission on
Human Rights appointed Paul
Hunt, a New Zealand national, 
as Special Rapporteur for a 
period of three years. In 2005, the Special Rapporteur’s
mandate was extended by a further three years. The man-
date of the Special Rapporteur is set out in Commission
on Human Rights resolutions on the right to health, in
particular resolution 2002/31 establishing the mandate.
The Special Rapporteur is required to submit annually a
report to the Human Rights Council and an interim report
to the General Assembly, detailing the activities per-
formed under his mandate. 
During his tenure as the Special Rapporteur on the
right to the highest attainable standard of health (2002-
2008), Paul Hunt regularly analysed the issue of access to
medicines as a component of the right to the highest
attainable standard of health. One focus of this work was
the responsibilities of pharmaceutical companies in rela-
tion to the right to health. This briefing is closely based
on the report on this subject that the Special Rapporteur
submitted to the UN General Assembly in 2008. The
report observes that a consensus is starting to emerge
that business enterprises, like all actors in society, have
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“Trying to run sexual and reproductive health 
programmes without contraceptives… and 
other reproductive health commodities is like 
trying to eradicate smallpox without vaccines. 
It simply cannot be done.” Steven Sinding, Director-General
International Planned Parenthood Federation, 2003
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some legal and ethical human rights responsibilities. 9
The application of human rights may vary from one type
of actor to another. For example, a State may be required
to implement a human right in one way (e.g. enact laws)
and a non-State actor in another way (e.g. reduce prices
for those living in poverty). But, the logic of human rights
will inevitably lead to their application, in one form or
another, to non-State actors.
This briefing examines the issue of access to medicines
in the context of sexual and reproductive health. Sexual
and reproductive health are key elements of the right to
the highest attainable standard of health. The briefing
considers the responsibilities of pharmaceutical compa-
nies for enhancing access to medicines. The briefing also
introduces the background and content of the Human
Rights Guidelines for Pharmaceutical Companies in
Relation to Access to Medicines (“the Guidelines”). Based
on the right to health responsibilities of pharmaceutical
companies, the Guidelines provide a framework for
enhancing access to medicines. 
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Ensuring the rights to sexual and reproductive health is
central to achieving the MDGs. 10 Sexual and reproductive
ill-health constitutes a significant proportion of the dis-
ease burden in developing countries. However a majority
of the population in these countries often does not 
have access to essential sexual and reproductive health
medicines. 11 According to WHO, it is estimated that 201
million couples are at risk of unintended pregnancy. These
are couples who would like to space or limit their births,
but are not using modern methods of contraception to do 
so. 12 A lack of access to medicines needed to maintain
sexual and reproductive health threatens the well-being
of individuals, families, and communities.
According to WHO, unsafe sex is the second most
important risk factor leading to disability, disease or death
in developing countries and the ninth most important in
developed countries. 13 Many of these problems can be
significantly reduced if sexual and reproductive health
medicines are available, accessible, of good quality, and
properly used. However, access to contraceptives, medi-
cines for preventing and treating sexually transmitted
infections (STIs), and drugs to support a healthy pregnan-
cy and safe delivery, requires an integrated approach,
involving governments and the corporate sector.
In this briefing paper we will examine the role of 
the pharmaceutical industry in ensuring access to 
medicines generally and in particular for sexual and
reproductive health. Before examining the responsibilities
of the pharmaceutical industry, the briefing examines the
relationship between two specific sexual and reproductive
health problems, HIV/AIDS and the human papillomavirus,
and access to medicines. 
There is a strong link between HIV/AIDS and sexual and
reproductive health. 14 The large majority of HIV infec-
tions are transmitted through unprotected sex or associ-
ated with pregnancy, childbirth and breastfeeding. In
addition, sexual and reproductive ill-health and HIV/AIDS
share root causes, including poverty, gender inequality
and social marginalization of the most vulnerable popula-
tions. 15 The international community agrees that the
MDGs will not be achieved without ensuring access to
sexual and reproductive health services and an effective
global response to HIV/AIDS.
The availability of antiretroviral therapy (ART) has sig-
nificantly reduced AIDS morbidity and mortality in devel-
oped countries. Yet in developing countries, where 95% of
HIV positive people live, the overwhelming majority still
does not have access to life-sustaining medication. 16
According to recent estimates, ART coverage still remains
low: only 31% of people estimated to be in need of treat-
ment in low-income and middle-income countries were
receiving it in 2007. 17 It is also reported that only 11 
I. MEDICINES AND SEXUAL 
AND REPRODUCTIVE HEALTH
A: HIV/AIDS AND MEDICINES
Sexual and reproductive health are vital elements of
the right to the highest attainable standard of
health. Sexual health is a state of physical, emotion-
al, mental and social well-being related to sexuality,
not merely the absence of disease, dysfunction or
infirmity (E/CN.4/2004/49). Reproductive health 
is a state of complete physical, mental and social
well-being and not merely the absence of disease or
infirmity, in all matters relating to the reproductive
system and to its functions and processes (Program
of Action of the International Conference on
Population and Development, Cairo, 1994). Many
elements of sexuality are non-reproductive: while
sexual and reproductive health are closely linked,
they are therefore also distinct. At the International
Conference on Population and Development the
international community recognised the importance
of human rights, including the right to health, for
guaranteeing sexual and reproductive health, both as
a goal in its own right and as a strategy for poverty
reduction. Not only have the rights to sexual and
reproductive health, and other related human rights,
often guided relevant policies and programmes, but
also legal protections in international and domestic
laws have been used to protect against, and provide
redress for, violations of these human rights.
Box 1: The rights to sexual and reproductive health
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percent of HIV pregnant women have access to interven-
tions designed to prevent mother-to-child transmission 
(MTCT). 18 MTCT is almost entirely preventable, provided
services are available and accessible. However in many
low-income and middle-income countries the coverage
levels are very low. 19 Long and short courses of single,
dual or triple antiretroviral prophylaxis have been shown
to reduce HIV transmission to infants. Short courses of
antiretroviral drugs, started in late pregnancy or during
labour, reduce the risk of in utero and peripartum 
HIV transmission two- to three-fold and are used in 
many countries. 20
The UN Committee on Economic, Social and Cultural
Rights, International Guidelines on HIV/AIDS and Human
Rights, as well as other international human rights bodies
and instruments, recognise the right to medical 
treatment, including access to medicines. 21 However, 
the enforcement of these rights is not evident in the 
current global situation, where often entire populations,
particularly the poor and underprivileged, have little or 
no access to even essential medicines. 22
The establishment of the Global Fund to Fight AIDS,
Tuberculosis, and Malaria, as well as the World Bank
Multi-Country HIV/AIDS Program, have provided develop-
ing countries with valuable resources and incentives to
improve their procurement of, and management systems
for, medicines. However, despite widespread global atten-
tion, scaling up effective medical care for people living
with HIV/AIDS (PLWHA) continues to pose a massive chal-
lenge. Enhancing access to HIV/AIDS treatment can only
be done by addressing the underlying issues that impact
upon access in the first place. Addressing 
these issues require an integrated approach
involving a number of sectors, including the
pharmaceutical industry. The social contract
demands pharmaceutical companies take
creative, wide-ranging steps to increase
access to medicines. 23 The Guidelines 
in section III highlight some of the
measures that, ‘if systematically 
implemented’, would enhance 
access to medicines.
Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines 5
Photograph © 2004
Samuel Makaka,
Courtesy of Photoshare.
HIV-positive babies are
visited by United Nations
representatives at a rural
clinic in Malawi, as part
of a UN envoy on
HIV/AIDS. Many people in
Malawi are persuaded by
the fact that when you
go for voluntary testing
and you are found HIV
positive, you are auto-
matically put on free
ARVs. Only 9,000 people
at the time of this visit
were on free ARVs.
Photograph © 2005
Alfredo L. Fort,
Courtesy of Photoshare.
Packages of antiretroviral
drugs sit on a table, wait-
ing to be dispensed to
AIDS patients in Katutura
Hospital, Windhoek,
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types 16 and 18, which are two high-risk types of HPV,
account for 65 percent of invasive cancers. 28
HIV-infected individuals are at higher risk of HPV infec-
tion and are infected by a broader range of HPV types. 29
According to a recent study nearly 40% of HIV-infected
women had an HPV infection. 30 Simultaneous infection
with multiple HPV genotypes is more common in HIV-
infected women than in non-HIV infected women. HIV-
infected men and women are also at increased risk of 
HPV associated anal cancer. 31
Cervical cancer is a gender-specific disease that dispro-
portionately affects women in the lowest socioeconomic
groups throughout the world. Widespread vaccination has
the potential to reduce cervical cancer deaths around the
world by as much as two-thirds. 32
In 2006, the U.S. Food and Drug Administration (FDA)
Human papillomavirus (HPV) is responsible for 99.7% of
cervical cancers. HPV is primarily spread through sexual
contact 24 and is associated with a wide-range of dis-
eases, including genital warts and many forms of cancer
in addition to cervical cancer. HPV is one of the most
common sexually transmitted diseases.
Cervical cancer and precancerous cervical lesions 
constitute a major problem for women's health. Every
year 470,000 cases of cervical cancer are diagnosed
worldwide, and about half the women afflicted will die
from the disease. 25 The incidence of cervical cancer dif-
fers between regions, particularly between high-income
and low-income countries. 26 Almost 80 percent of cases
occur in low-income countries, where cervical cancer is
the most common. In Western Europe, some 30,000 new
cases per year are diagnosed and about 15,000 deaths 
are recorded. 27 In sub-Saharan Africa and Latin America
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In May 2000, a partnership of five international
organisations (UNAIDS Secretariat, WHO, UNICEF, 
UNFPA and the World Bank) and seven research and
development-based pharmaceutical companies
(Abbott Laboratories, Boehringer-Ingelheim, Bristol-
Myers Squibb, Gilead Sciences, GlaxoSmithKline, F.
Hoffmann-La Roche and Merck & Co., Inc.) was
launched to accelerate access to care and treatment
for HIV/AIDS. AAI is designed to improve access to
more affordable HIV medicines and diagnostics for
least-developed countries and others hardest hit by
the pandemic in the context of a broader framework
of care, treatment and support. 
AAI aims to increase sustained access to 
appropriate, good quality interventions (including
antiretrovirals therapy) through new alliances 
involving committed governments, industry, the UN
agencies, development organisations, NGOs and peo-
ple living with HIV/AIDS.
More information on AAI can be found at www.gsk.com/
responsibility/cr_report_2004/la_aids.htm 
Box 2: Accelerating Access Initiative (AAI)
B: HUMAN PAPILLOMAVIRUS AND MEDICINES
Pharmaceutical companies manufacturing the
vaccines... should develop culturally appropriate
information packages to avoid a negative 
reaction against the vaccination
MEDICINES AND SEXUAL AND REPRODUCTIVE HEALTH
approved Gardasil, a vaccine that prevents persistent
infection with HPV types 16 and 18, which cause most
(70 percent) cervical cancers worldwide, and types 6 and
11, which cause virtually all (90 percent) genital warts. 33
Another vaccine that recently received FDA approval is
Cervarix which is produced by GlaxoSmithKline (GSK).
Cervarix also protects against persistent infection with
HPV types 16 and 18.
Currently, the vaccinations are very costly and 
thus unaffordable to many millions in low-income and
middle-income countries. In order to prevent widening
the access gap, strong public-private partnerships need 
to be forged. States, the United Nations Population 
Fund (UNFPA), WHO, global alliances such as the Global
Alliance for Vaccines and Immunisations (GAVI) and 
pharmaceutical companies can play an important role 
in ensuring access to vaccination to all those in need.
Further, there are severe misconceptions about HPV 
and the vaccinations. Misconceptions are grounded in
moral, religious, political, economic, and socio-cultural
arguments. For instance it is argued that the vaccine
increases sexual risk-taking, sends mixed messages 
about abstaining from sexual intercourse and usurps
parental authority. 34 Pharmaceutical companies 
manufacturing the vaccines, such as Merck (Gardasil) 
and GSK (Cervarix), should develop culturally appropriate
information packages to avoid a negative reaction against
the vaccination. Critically, if access it to be enhanced,
prices must come down.
The Guidelines in section III of this briefing provide
guidance for ensuring the availability and accessibility 
of vaccinations for immunisation against serious 
sexual and reproductive health problems, 
such as HPV. 
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UNFPA and WHO have agreed a list of drugs 
and commodities to be procured for key needs 
in the area of sexual and reproductive health. 
This includes:
 A full range of contraceptives (such as hormonal
methods, intrauterine devices, barrier methods,
and subdermal implants).
 Maternal and neonatal healthcare commodities
(anesthetics, analgesics, antibacterials, anticonvul-
sants, antiseptics/disinfectants, oxytocics, vac-
cines, and vitamins, among others, including
equipment for emergency obstetric care).
 Reproductive tract infection commodities 
(diagnostic tests and first-line drugs).
 HIV prevention commodities (male and female
condoms and drugs to prevent mother-to-child
transmission).
 General equipment and supplies for providing 
primary and secondary healthcare (sterilizing
equipment, lighting, anesthetics and their 
equipment and supplies, oxygen, postoperative
medication, operating theater equipment, ward
equipment, drugs for gastric acidosis, muscle
relaxation, and anaphylaxis, and cholinesterase
inhibitors).
Source: UNFPA and WHO 2003.
Box 3: Essential sexual and reproductive health medicines and supplies
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II. HUMAN RIGHTS GUIDELINES FOR 
PHARMACEUTICAL COMPANIES IN 
RELATION TO ACCESS TO MEDICINES: 
BACKGROUND AND CONTEXT 
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States have primary responsibility for enhancing access 
to medicines. Between 2002-2008, the Special Rapporteur
regularly scrutinised States’ duties in relation to access 
to medicines. For example, these duties are the main
focus of a chapter on the human right to medicines in
one of his reports to the General Assembly (see Box 4)
and are a key theme during several of his country mis-
sions, including to Uganda and Peru and reports on 
these missions. 35 Another report looks at States’ 
duties in relation to access to medicines and the World
Trade Organisation. 36 Some of his press statements 
have focussed on States’ duties in relation to access 
to medicines. 37 Also, some of his other publications 
have examined States’ duties in relation to access to
medicines, such as Neglected diseases: A human 
rights analysis. 38
States have to do all they reasonably can to make
sure that existing medicines are available in suffi-
cient quantities in their jurisdictions. For example,
they might have to make use of the Agreement on
Trade-Related Aspects of Intellectual Property Rights
(TRIPS) flexibilities by passing and using compulsory
licence legislation, thereby ensuring that medicines
reach their jurisdictions in adequate quantities.
Historically, research and development has not
addressed the priority health needs of low-income
and middle-income countries. Thus, within a frame-
work of international assistance and cooperation,
States are required to take effective measures to
promote the development and availability of new
drugs, vaccines and diagnostic tools for those dis-
eases causing a heavy burden in developing coun-
tries. States therefore are required to resort to a
variety of economic, financial and commercial 
incentives in order to influence research and 
development into specific health needs.
In short, States not only have a duty to ensure
that existing medicines are available within their
borders, they also have a responsibility to take 
reasonable measures to ensure that much-needed
new medicines are developed and thereby become
available.
In addition to being available, medicines must 
also be accessible. Accessibility has four dimensions.
First, medicines must be accessible in all parts of the
country (for example, in remote rural areas as well 
as in urban centres). This has major implications for
the design of medicine supply systems, including
outreach programmes. Second, medicines must 
be economically accessible (i.e. affordable) to all,
including those living in poverty. This has major
implications for medicine funding and pricing
arrangements. It may also mean that a State has to
revisit import duties and other taxes on medicines if
they are helping to take medicines beyond the reach
of the poor. Third, medicines must be accessible
without discrimination on any of the prohibited
grounds, such as sex, race, ethnicity and socio-
economic status. The principle of non-discrimination
may require a State to take measures to ensure
equality of access for all individuals and groups, 
such as disadvantaged minorities. Fourth, reliable
information about medicines must be accessible to
patients and health professionals so they can take
well-informed decisions and use medicines safely.
As well as being available and accessible, 
medicines and associated issues must be culturally
acceptable and respectful of medical ethics. For
example, national measures should support the prop-
er use of traditional medicine and its integration into
health-care systems, while clinical trials must ensure
the informed consent of research subjects.
Medicines must also be of good quality. If rejected in
the North because they are beyond their expiry date
and unsafe, medicines must not be recycled to the
South. Because medicines may be counterfeit or
tampered with, States must establish a regulatory
system to check medicine safety and quality.
Source: Report of the UN Special Rapporteur on the right to the
highest attainable standard of health (A/61/338)
Box 4: The responsibilities of States to ensure that medicines are available, accessible,
culturally acceptable and of good quality
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On numerous occasions over the last six years,
Ministers, senior public officials and others have informed
the Special Rapporteur that, when endeavouring to
implement the right to the highest attainable standard of
health, States encounter many obstacles. Among the
obstacles they have mentioned, two stand out. First, the
policies and practices of donor countries; for this reason,
the Special Rapporteur has looked, on numerous occa-
sions in several reports, at the role of donors, most
recently in his report on Sweden as a donor. 39
Second, Ministers, senior public officials and others
have argued that the policies and practices of some 
pharmaceutical companies constitute obstacles to States’
implementation of the right to the highest attainable
standard of health and, in particular, their endeavours to
enhance access to medicines. They have mentioned, for
example, excessively high prices, inadequate attention to
research and development concerning diseases that dis-
proportionately impact people in developing countries,
inappropriate drug promotion, and problematic clinical
trials. Ministers and senior public officials have also
acknowledged, however, that the pharmaceutical sector
has an indispensable role to play in relation to the right
to health and access to medicines. Moreover, they have
recognised the constructive contribution of specific 
pharmaceutical companies.
The Special Rapporteur’s mandate expressly requires
him to identify, inter alia, obstacles to the implementation
of the right to the highest attainable standard of health.
He is also expressly mandated to report on good practices,
and to make recommendations, that will help to promote
and protect the right to the highest attainable standard
of health.
Although States have primary responsibility for ensur-
ing both the right to the highest attainable standard of
health and enhancing access to medicines, this is a shared
responsibility. If access to medicines is to be enhanced,
numerous national and international actors have an
indispensable role to play. The Millennium Development
Goals recognise that pharmaceutical companies are
among those sharing this responsibility. Goal 8, a global
partnership for development, has a number of targets, not
least: “In cooperation with pharmaceutical companies,
provide access to affordable, essential drugs in developing
countries” (emphasis added).
Between 2003-2006, the Special Rapporteur engaged in
many discussions on access to medicines with numerous
parties, including pharmaceutical companies. These sub-
stantive discussions took place at symposia and work-
shops, as well as informal visits to pharmaceutical compa-
nies. They were informed by the work of States, pharma-
ceutical companies (and their associations, such as the
International Federation of Pharmaceutical Manufacturers
and Associations), United Nations Global Compact, Office
of the High Commissioner for Human Rights (OHCHR),
WHO and other elements of the United Nations system,
Business Leaders Initiative on Human Rights, numerous
civil society organisations, and others. More recently, the
Special Rapporteur has benefited from the reports of the
Special Representative of the Secretary-General on the
issue of human rights and transnational corporations and
other business enterprises.
During these numerous discussions, the human rights
duties of States in relation to access to medicines were
reasonably clear, and these duties are now explored, in
considerable detail, in the Special Rapporteur’s various
reports. 40 However, it became apparent during these dis-
cussions that the nature and scope of pharmaceutical
companies’ human rights responsibilities in relation to
access to medicines were not clear. The United Nations
Committee on Economic, Social and Cultural Rights, for
example, confirms that the private business sector has
responsibilities regarding the realisation of the right to
the highest attainable standard of health, but it has not
taken further steps to specify these responsibilities. 41
While the Committee’s general statement of principle is
very important, it provides no practical guidance about
the human rights responsibilities of pharmaceutical 
companies in relation to access to medicines.
It became imperative, therefore, to address this situa-
tion. How can pharmaceutical companies sensibly be
asked to respect their human rights responsibilities in
relation to access to medicines without much more 
specific guidance, as well as the identification of good
practices? How can they be monitored, and held to
account, if their human rights responsibilities in relation
to access to medicines are unclear?
In an effort to shape a collaborative approach aimed at
addressing these questions, a series of substantive meet-
ings with a number of major pharmaceutical companies,
and civil society groups, was organised by the Special
Rapporteur and Mary Robinson, President of Realizing
Rights: Ethical Globalization Initiative and former UN
High Commissioner for Human Rights. The result of these
discussions was a two-phase proposal suggesting a 
way forward. This proposal was discussed at length with
the companies involved and revised to accommodate a
number of their concerns.
First, it was suggested that a small group of human
rights experts, and representatives from pharmaceutical
companies, work together to identify as much common
ground as possible, as well as good faith disagreements, 
in relation to pharmaceutical companies’ human rights
responsibilities and access to medicines. It was proposed
that this process would take two years and would gener-
ate an important, useful report that clarified what can
A: BACKGROUND AND DRAFTING HISTORY
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properly be asked of pharmaceutical companies in 
relation to access to medicines and human rights.
The second part of the proposal outlined a process
through which a small group of experts would then be
appointed, by consensus among those participating in the
initiative, to use this report to evaluate the policies and
practices of certain pharmaceutical companies. These
evaluations would be made public. This second phase
would last for an initial period of three years.
The hallmark of this two-phase, five-year proposal was
constructive cooperation and collaboration with a number
of major pharmaceutical companies.
To their credit, two companies, Novartis and
NovoNordisk, were willing to proceed with the proposal.
Unfortunately, however, the majority of companies
involved in the initiative were unwilling to go-ahead.
Reluctantly, the Special Rapporteur and Mrs Robinson
decided that buy-in from only two companies was 
insufficient for what was designed to be a collaborative
initiative engaging a range of major pharmaceutical 
companies. It was agreed that there was no choice, 
unfortunately, other than to put the proposal aside.
The regrettable refusal of some pharmaceutical 
companies to engage in this collaborative project 
did not diminish the need to pursue the central 
objective. Given that some States allege that the 
practices of some pharmaceutical companies are 
obstacles to access to medicines, the urgent need
remained for greater clarity regarding the human 
rights responsibilities of pharmaceutical companies 
in relation to access to medicines.
Of course, the long-term goal is the development of
internationally recognised human rights guidelines for
both States and pharmaceutical companies in relation to
access to medicines. However, there is greater clarity
about the human rights responsibilities of States than
there is about the responsibilities of pharmaceutical com-
panies regarding access to medicines. As already observed,
several reports of the Special Rapporteur explore the
access to medicines responsibilities of States. Indeed, one
report applies the right-to-health analytical framework
and sets out in detail the numerous human rights respon-
sibilities of States in relation to access to medicines. 42
There is no comparable human rights guidance for phar-
maceutical companies in relation to access to medicines.
In these circumstances, the Special Rapporteur’s priority
focus was on human rights guidelines for pharmaceutical
companies in relation to access to medicines.
Thus, as signalled in his 2006 report to the General
Assembly, 43 the Special Rapporteur embarked on a
process of preparing, for consultation, draft human rights
guidelines for pharmaceutical companies in relation to
access to medicines. This process drew heavily upon the
extensive discussions with pharmaceutical companies and
others that had taken place between 2003-2006. There
were additional consultations, too. In 2007, for example,
the University of Toronto organised a multi-stakeholder
workshop, attended by pharmaceutical companies.
This process led to the publication of draft Human
Rights Guidelines for Pharmaceutical Companies in rela-
tion to Access to Medicines in September 2007. The draft
was available for public comment until 31 December
2007; to allow as much consultation as possible, this
deadline was postponed until 31 March and again until
15 May 2008. To facilitate consultation, the draft was
placed on the websites of the Office of the High
Commissioner for Human Rights, as well as the Human
Rights Centre, University of Essex. The draft was also
posted on numerous other websites, too.
Since September 2007, the Special Rapporteur actively
sought comments on the draft. In October, the
Government of Brazil held an open consultation, attended
by States, in the main UN building in New York. There
were two consultations with a number of major institu-
tional investors; one consultation took place in New York,
the other in London. The draft was discussed with WHO
and, on two occasions, with the International Federation
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of Pharmaceutical Manufacturers and Associations. Other
non-governmental organisations were also consulted.
Unfortunately, when the Special Rapporteur
approached some pharmaceutical companies to meet 
and discuss the draft all declined, with the honourable
exception of NovoNordisk. A few companies sent helpful 
written comments on the draft. Some forty stakeholders
sent written comments, all of which were placed on the
web, with a small handful of exceptions where confiden-
tiality was requested.
In summary, extensive written and oral comments 
on the draft were received from a very wide range of
stakeholders encompassing States, institutional investors,
pharmaceutical companies, specialised agencies, national
human rights institutions, non-governmental organisa-
tions, academics and others. 
When the Special Rapporteur informed the General
Assembly in October 2006 that he intended to prepare
draft guidelines, he was encouraged to proceed with this
challenging project.
The draft Guidelines of September 2007 were extensively
revised in light of the very numerous written and oral
comments. The final version of the Guidelines is in the
next section of this briefing. Beginning with a Preamble,
the Guidelines are grouped by themes, such as trans-
parency, management, monitoring and accountability,
pricing and ethical marketing. Each theme is followed by
a brief Commentary.
The Guidelines should be read with the Special
Rapporteur’s report to the General Assembly on access to
medicines. 44 This report includes a section on the respon-
sibilities of States and another on the responsibilities of
pharmaceutical companies. This discussion and analysis
will not be repeated here. Instead, some inter-related
points are briefly emphasised.
Health systems 
At the heart of the right to the highest attainable 
standard of health lies an effective and integrated health
system, encompassing medical care and the underlying
determinants of health, which is responsive to national
and local priorities, and accessible to all. Medical care and
access to medicines are vital elements of an effective,
integrated, responsive and accessible health system.
Crucially, their full realisation depends upon such a 
system being in place. In many countries, however, 
health systems are failing and collapsing (see the 
Special Rapporteur’s report A/HRC/7/11). There are, in
many countries, extremely grave systemic obstacles to
enhancing access to medicines, such as clinics without
health workers and the most basic facilities. While imme-
diate steps can be taken by a range of actors to enhance
access to medicines, it is imperative that systemic obsta-
cles are recognised and tackled as a matter of priority 
and urgency. 
Enhancing shareholder value
Pharmaceutical companies operate in complex market
and social settings that give rise to a range of responsibil-
ities to various stakeholders. Of course, companies have a
responsibility to enhance shareholder value. This responsi-
bility has to be seen in the context of other social, devel-
opmental and human rights responsibilities, especially the
pharmaceutical sector’s central societal mission to devel-
op high quality medicines that are accessible to those in
need. Moreover, all pharmaceutical companies would find
it beneficial to adopt a rights-sensitive approach to their
businesses, as outlined in the excellent joint publication of
the United Nations Global Compact, Business Leaders
Initiative on Human Rights, and OHCHR. 45
B: THE GUIDELINES
The 2004 Pharmaceutical Shareowners Group (PSG)
recognised that there was a high level of consensus
about the potential significance of the issue and the
business case for a proactive response. The following
drivers were recognised by the PSG:
• Defending the ‘social contract’ between govern-
ments and pharmaceutical companies, upon which
intellectual property law and future innovation
depends;
• Limiting the potential for emerging markets to opt
out of international patent treaties;
• Protecting company reputation and license to
operate with potential impacts on pricing power in
the USA and other lucrative markets;
• Building political goodwill to help secure future
markets;
• Improving stakeholders relations; 
• Enhancing employee morale and recruitment
prospects.
Source: PSG, The Public Health Crisis in Emerging Markets,
September 2004.
Box 5: A business case for human rights
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Practical, constructive guidance
The Guidelines do not use the peremptory word “must”,
but the more modest language “should”. In other words,
they deliberately avoid some of the most controversial
doctrinal questions (such as, “are businesses legally bound
by international human rights law?”) that have dominated
debates about business and human rights for many years.
These discussions are important, and the Special
Rapporteur has contributed to them elsewhere, but the
central objective of the Guidelines is to provide practical,
constructive and specific guidance to pharmaceutical
companies and other interested parties, including those
who wish to monitor companies and hold them to
account. 46 The Guidelines are consistent with and com-
plementary to the helpful analysis recently provided by
the Special Representative of the Secretary-General on
the issue of human rights and transnational corporations
and other business enterprises.
The Guidelines are based on human rights principles
that are enshrined in the Universal Declaration of
Human Rights (UDHR), including non-discrimination,
equality, transparency, monitoring and accountabili-
ty. The Guidelines are also informed by human rights,
such as some features of the right to the highest
attainable standard of health. As the Constitution of
the World Health Organisation affirms, “enjoyment
of the highest attainable standard of health is one of
the fundamental rights of every human being”. UDHR
lays the foundations for the international framework
for this fundamental human right, now codified 
in numerous national constitutions, as well as 
international human rights treaties, including 
the Convention on the Rights of the Child and
International Covenant on Economic, Social and
Cultural Rights. The Guidelines also draw from other
widely accepted standards, such as instruments on
medicines adopted by the World Health Organisation
in recent years.
Box 6: Key human rights standards upon which the Guidelines are based
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III. HUMAN RIGHTS GUIDELINES FOR 
PHARMACEUTICAL COMPANIES IN 
RELATION TO ACCESS TO MEDICINES
a. Almost two billion people lack access to essential medicines; improving access to existing medicines could save
ten million lives each year, four million of them in Africa and South-East Asia.
b. Millennium Development Goals, such as reducing child mortality, improving maternal health, and combating
HIV/AIDS, malaria and other diseases, depend upon improving access to medicines.
c. One of the Millennium Development Goal targets is, “in cooperation with pharmaceutical companies, (to) 
provide access to affordable essential drugs in developing countries.”
d. Medical care and access to medicines are vital features of the right to the highest attainable standard 
of health.
e. Access to medicines depends upon effective, integrated, responsive and accessible health systems. In many
countries, health systems are failing and collapsing, constituting a grave obstacle to increasing access to 
medicines. While a range of actors can take immediate steps to increase access to medicines, health systems
must be strengthened as a matter of priority and urgency.
f. States have the primary responsibility for realising the right to the highest attainable standard of health and
increasing access to medicines.
g. In addition to States, numerous national and international actors share a responsibility to increase access 
to medicines.
h. As confirmed by the United Nations Global Compact, the Special Representative of the Secretary General on
Human Rights and Transnational Corporations and Other Business Enterprises, the Committee on Economic,
Social and Cultural Rights, the Business Leaders Initiative on Human Rights, and many others, the private 
business sector has human rights responsibilities.
i. Pharmaceutical companies, including innovator, generic and biotechnology companies, have human rights
responsibilities in relation to access to medicines.
j. Pharmaceutical companies also have other responsibilities, for example, a responsibility to enhance 
shareholder value.
k. Pharmaceutical companies are subject to several forms of internal and external monitoring and accountability;
however, these mechanisms do not usually monitor, and hold a company to account, in relation to its human
rights responsibilities to enhance access to medicines.
l. Pharmaceutical companies contribute in various ways to the realisation of the right to the highest attainable
standard of health, such as providing individuals and communities with important information about public
health issues. Enhancing access to medicines, however, has the central place in the societal mission of pharma-
ceutical companies. For this reason, these non-exhaustive, inter-related Guidelines focus on the human rights
responsibilities of pharmaceutical companies in relation to access to medicines.
m. Pharmaceutical companies’ human rights responsibilities are not confined to the right to the highest attainable
standard of health. They have human rights responsibilities, for example, regarding freedom of association and
conditions of work. These human rights responsibilities, however, are not addressed in these Guidelines.
n. While most of the Guidelines address issues that are highly relevant to all pharmaceutical companies, including
innovator, generic and biotechnology companies, a few of the Guidelines address issues of particular relevance
to some companies within the pharmaceutical sector.
o. These Guidelines apply to pharmaceutical companies and their subsidiaries.
PREAMBLE
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p. These Guidelines are based on human rights principles enshrined in the Universal Declaration of Human Rights,
including non-discrimination, equality, transparency, monitoring and accountability. The Constitution of the
World Health Organisation affirms that the “enjoyment of the highest attainable standard of health is one of
the fundamental rights of every human being”. This fundamental human right is codified in numerous national
constitutions, as well as international human rights treaties, including the Convention on the Rights of the
Child and International Covenant on Economic, Social and Cultural Rights. Accordingly, these Guidelines are
informed by some features of the right to the highest attainable standard of health, such as the requirement
that medicines are of good quality, safe and efficacious. The Guidelines also draw from other widely accepted
standards, such as instruments on medicines adopted by the World Health Organisation.
q. For the purposes of these Guidelines, medicines include active pharmaceutical ingredients, diagnostic tools, 
vaccines, biopharmaceuticals and other related healthcare technologies.
r. For the purposes of these Guidelines, neglected diseases are defined as those diseases primarily affecting those
living in poverty, especially in rural areas, in low-income countries. Sometimes called tropical or poverty-related
diseases, they include, for example, leishmaniasis (kala-azar), onchocerciasis (river blindness), Chagas disease,
leprosy, schistosomiasis (bilharzias), lymphatic filariasis, African trypanosomiasis (sleeping sickness) and dengue.
Although in recent years HIV/AIDS, tuberculosis and malaria have attracted increasing attention and resources,
they may also be regarded as neglected diseases.
s. These Guidelines adopt the World Bank definition of low-income, middle-income and high-income countries.
1 The company should adopt a human rights policy statement which expressly recognises the importance of
human rights generally, and the right to the highest attainable standard of health in particular, in relation
to the strategies, policies, programmes, projects and activities of the company.
2 The company should integrate human rights, including the right to the highest attainable standard of
health, into the strategies, policies, programmes, projects and activities of the company.
3 The company should always comply with the national law of the State where it operates, as well as any 
relevant legislation of the State where it is domiciled.
4 The company should refrain from any conduct that will or may encourage a State to act in a way that is
inconsistent with its obligations arising from national and international human rights law, including the
right to the highest attainable standard of health.
Commentary
Formal, express recognition of the importance of human rights, and the right to the highest attainable standard 
of health, helps to establish a firm foundation for the company’s policies and activities on access to medicines
(Guideline 1). Such recognition, however, is not enough: operationalisation is the challenge (Guideline 2). Many 
of the Guidelines signal ways in which right-to-health considerations can be operationalised and integrated into
the company’s activities. There are numerous national and international (including regional) legal provisions that
safeguard aspects of the right to the highest attainable standard of health. It is axiomatic that they must be
respected, at all times, by all pharmaceutical companies, in accordance with elementary principles of corporate
good governance (Guidelines 3-4).
GENERAL
5 Whenever formulating and implementing its strategies, policies, programmes, projects and activities that
bear upon access to medicines, the company should give particular attention to the needs of disadvantaged
individuals, communities and populations, such as children, the elderly and those living in poverty. 
The company should also give particular attention to the very poorest in all markets, as well as 
gender-related issues. 
DISADVANTAGED INDIVIDUALS, COMMUNITIES AND POPULATIONS
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Commentary
Equality and non-discrimination are among the most fundamental features of international human rights, 
including the right to the highest attainable standards of health. They are akin to the crucial health concept 
of equity. Equality, non-discrimination and equity have a social justice component. Accordingly, the right to the
highest attainable standard of health has a particular pre-occupation with disadvantaged individuals, communities
and populations, including children, the elderly and those living in poverty. Like equity, the right-to-health also
requires that particular attention be given to gender. All the other Guidelines must be interpreted and applied in
the light of Guideline 5, which has fundamental importance.
6 In relation to access to medicines, the company should be as transparent as possible. There is a presump-
tion in favour of the disclosure of information, held by the company, which relates to access to medicines.
This presumption may be rebutted on limited grounds, such as respect for the confidentiality of personal
health data collected during clinical trials.
7 In conjunction with other pharmaceutical companies, the company should agree to standard formats for
the systematic disclosure of company information and data bearing upon access to medicines, thereby
making it easier to evaluate the performance of one company against another, as well as the performance
of the same company over time.
8 Either alone or in conjunction with others, the company should establish an independent body to 
consider disputes that may arise regarding the disclosure or otherwise of information relating to access to
medicines. This body may be the monitoring and accountability mechanism referred to in Guideline 14.
Commentary
Transparency is another cardinal principle of international human rights, including the right to the highest attain-
able standard of health. It is not possible to properly understand and meaningfully evaluate access to medicines
policies and practices without the disclosure of key information. There is a presumption in favour of disclosure,
which may be rebutted on limited grounds (Guideline 6). Commonsense confirms that the principle of transparency
not only requires that information be made publicly available, it also requires the information be made publicly
available in a form that is accessible, manageable and useful (Guideline 7). An independent, trusted and informal
body should be established to consider any disputes that may arise about whether or not a particular piece of
information relating to access to medicines should be disclosed (Guideline 8). This body should also provide 
guidance on the legitimate grounds of non-disclosure. While Guidelines 6-8 have general application to access to
medicines, other Guidelines apply the cardinal principle of transparency in specific contexts, such as public policy
influence, advocacy and lobbying (Guidelines 17-19).
TRANSPARENCY
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15 A company should publicly adopt effective anti-corruption policies and measures, and comply with relevant
national law implementing the United Nations Convention against Corruption. 
16 In collaboration with States, the company should take all reasonable measures to address counterfeiting.
Commentary
Corruption is a major obstacle to the enjoyment of the right to the highest attainable standard of health, including
access to medicines. Those living in poverty, for example, are disproportionately harmed by corruption because they
CORRUPTION
16 Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines
HUMAN RIGHTS GUIDELINES FOR PHARMACEUTICAL COMPANIES IN RELATION TO ACCESS TO MEDICINES
9 The company should encourage and facilitate multi-stakeholder engagement in the formulation of its 
policies, programmes, projects and other activities that bear upon access to medicines. In keeping with
Guideline 5, this engagement should include the active and informed participation of disadvantaged 
individuals, communities and populations. 
10 The company should have a publicly available policy on access to medicines setting out general and specific
objectives, time frames, reporting procedures, and lines of accountability. 
11 The company should have a governance system that includes direct board-level responsibility and 
accountability for its access to medicines policy.
12 The company should have clear management systems, including quantitative targets, to implement and
monitor its access to medicines policy.
13 The company should publish a comprehensive annual report, including qualitative and quantitative 
information, enabling an assessment of the company’s policies, programmes, projects and other activities
that bear upon access to medicines.
14 In the context of access to medicines, internal monitoring and accountability mechanisms have a vital 
role to play, but they should also be supplemented by a mechanism that is independent of the company.
Until such a mechanism is established by others, the company should establish an effective, transparent,
accessible and independent monitoring and accountability mechanism that:
i. assesses the impact of the company’s strategies, policies, programmes, projects and activities on access
to medicines, especially for disadvantaged individuals, communities and populations;
ii. monitors, and holds the company to account in relation to, these Guidelines.
Commentary
All human rights, including the right to the highest attainable standard of health, require effective, transparent and
accessible monitoring and accountability mechanisms. The mechanisms have a variety of forms; usually a mix of
mechanisms is required. While some mechanisms are internal, others are external and independent; both types are
needed. Guidelines 9-13 address the issue of internal corporate monitoring and accountability regarding access to
medicines. Guideline 14 addresses the issue of an external, independent monitoring and accountability mechanism
regarding access to medicines. 
MANAGEMENT, MONITORING AND ACCOUNTABILITY
Corruption is a major obstacle 
to the enjoyment of the right 
to the highest attainable 
standard of health, including
access to medicines
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are less able to pay for private alternatives where corruption has depleted public health services. Numerous 
features of the right to the highest attainable standard of health, such as transparency, monitoring and accounta-
bility, help to establish an environment in which corruption can neither thrive nor survive. In short, a right-to-
health policy is also an anti-corruption policy. As emphasised in the Preamble, improving access to medicines is a
responsibility shared by numerous national and international actors; Guideline 16 provides one specific example of
this shared responsibility in relation to counterfeiting. 47
17 The company should disclose all current advocacy and lobbying positions, and related activities, at the
regional, national and international levels, that impact or may impact upon access to medicines. 
18 The company should annually disclose its financial and other support to key opinion leaders, patient 
associations, political parties and candidates, trade associations, academic departments, research centres
and others, through which it seeks to influence public policy and national, regional and international law
and practice. The disclosure should extend to amounts, beneficiaries and channels by which the support 
is provided.
19 When providing any financial or other support, the company should require all recipients to publicly 
disclose such support on all appropriate occasions.
Commentary
Like many other businesses, pharmaceutical companies devote considerable resources to advocacy, lobbying and
related activities. While some of these activities may impact positively on access to medicines, for example, lobbying
to lower taxes on medicines, other activities may impact negatively. Guidelines have already emphasised, in general
terms, the central importance of transparency in relation to access to medicines (Guidelines 6-8). Guidelines 17-19
apply this general principle of transparency to the specific context of public policy influence, advocacy and lobbying.
PUBLIC POLICY INFLUENCE, ADVOCACY AND LOBBYING
20 The company should manufacture medicines that comply with current World Health Organisation Good
Manufacturing Practice Guidelines, as well as other appropriate international regulatory requirements 
for quality, safety and efficacy. 
Commentary
Guideline 20 reflects the elementary right-to-health requirement that all medicines must be of good quality, safe
and efficacious.
QUALITY
21 A company’s clinical trials should observe the highest ethical and human rights standards, including 
non-discrimination, equality and the requirements of informed consent. This is especially vital in those
States with weak regulatory frameworks. 
22 The company should conform to the Declaration of Helsinki on Ethical Principles for Medical Research
Involving Human Subjects, as well as the World Health Organisation Guidelines for Good Clinical Practice. 
Commentary
The right to the highest standard of health encompasses medical ethics. Guidelines 21-22 emphasise the right-to-
health responsibility of pharmaceutical companies to observe the leading international standards on ethics and
clinical trials. Guidelines 9-14 emphasise the importance of effective, transparent and accessible monitoring and
accountability mechanisms; these mechanisms should monitor, and hold to account, pharmaceutical companies in
relation to their policies and practices on clinical trials.
CLINICAL TRIALS
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23 The company should make a public commitment to contribute to research and development for neglected
diseases. Also, it should either provide in-house research and development for neglected diseases, or 
support external research and development for neglected diseases, or both. In any event, it should publicly
disclose how much it contributes to and invests in research and development for neglected diseases. 
24 The company should consult widely with the World Health Organisation, WHO/TDR 48 and other relevant
organisations, including leading civil society groups, with a view to enhancing its contribution to research
and development for neglected diseases. 
25 The company should engage constructively with key international and other initiatives that are searching
for new, sustainable and effective approaches to accelerate and enhance research and development for
neglected diseases.
Commentary
By providing an incentive for pharmaceutical companies to invest in research and development, the intellectual
property regime makes a major contribution to the discovery of new medicines that save lives and reduce suffering.
Where there is no economically viable market, however, the incentive is inadequate and the regime fails to gener-
ate significant innovation. For this reason, a different approach is needed to address the vitally important right-to-
health challenge of neglected or poverty-related diseases. Defined in the Preamble, neglected diseases mainly
afflict the poorest people in the poorest countries. The record shows that research and development has not
addressed key priority health needs of low-income and middle-income countries. More specifically, research and
development has given insufficient attention to neglected diseases. There is evidence, however, that some pharma-
ceutical companies are taking active measures to reverse this trend. 49 The right to the highest attainable standard
of health not only requires that existing medicines are accessible, but also that much-needed new medicines are
developed as soon as possible. Neglected diseases demand special attention because they tend to afflict the most
disadvantaged (Guideline 5). Guideline 23 does not make the unreasonable demand that all companies provide 
in-house research and development for neglected diseases. Rather, all companies should make some contribution
towards research and development for neglected diseases. Guidelines 23-25 signal other steps that companies
should take to address the historic neglect of poverty-related diseases. 
NEGLECTED DISEASES
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26 The company should respect the right of countries to use, to the full, the provisions in the Agreement on
Trade-Related Aspects of Intellectual Property Rights (TRIPS) (1994), which allow flexibility for the purpose
of promoting access to medicines, including the provisions relating to compulsory licensing and parallel
imports. The company should make and respect a public commitment not to lobby for more demanding
protection of intellectual property interests than those required by TRIPS, such as additional limitations on
compulsory licensing. 
27 The company should respect the letter and spirit of the Doha Declaration on the TRIPS Agreement 
and Public Health (2001) that recognises a State’s right to protect public health and promote access to
medicines for all. 
28 The company should not impede those States that wish to implement the World Trade Organisation
Decision on Implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and 
Public Health (2003) by issuing compulsory licences for exports to those countries, without manufacturing
capacity, encompassed by the Decision.
29 Given that some least-developed countries are exempt from World Trade Organization rules requiring the
granting and enforcing patents until 2016, the company should not lobby for such countries to grant or
enforce patents.
30 As part of its access to medicines policy, the company should issue non-exclusive voluntary licences with a
view to increasing access, in low-income and middle-income countries, to all medicines. The licences, which
may be commercial or non-commercial, should include appropriate safeguards, for example, requiring that
the medicines meet the standards on quality, safety and efficacy set out in Guideline 20. They should also
include any necessary transfer of technology. The terms of the licences should be disclosed.
31 As a minimum, the company should consent to National Drug Regulatory Authorities using test data 
(i.e. the company should waive test data exclusivity) in least-developed countries and also when a 
compulsory licence is issued in a middle-income country. 
32 In low-income and middle-income countries, the company should not apply for patents for insignificant or
trivial modifications of existing medicines.
Commentary
The preceding Commentary recognises the major contribution made by the intellectual property regime to the 
discovery of life-saving medicines. Crucially, this regime contains various ‘flexibilities’ and other features that 
are designed to protect and promote access to existing medicines. Carefully constructed, they were agreed, after
protracted negotiations, by the world community of States. Because they protect and promote access to existing
medicines, which is a key component of the right to the highest attainable standard of health, these ‘flexibilities’
and other features should not be limited, diminished or compromised. Some of the key ‘flexibilities’ and other fea-
tures are addressed in Guidelines 26-29. In brief, pharmaceutical companies should not seek to limit, diminish or
compromise the ‘flexibilities’ and other features of the intellectual property regime that are designed to protect
and promote access to existing medicines. Voluntary licences have a vital role to play in extending access to medi-
cines (Guideline 30). Consistent with a company’s responsibility to enhance shareholder value, commercial voluntary
licences are designed to generate revenue for the patent holder. The terms of the licences should include appropri-
ate safeguards, for example, relating to the quality, safety and efficacy of the product. Non-exclusive licences are
more likely to extend access than exclusive licences. Voluntary licences respect, and depend upon, the intellectual
property regime. Because data exclusivity has the potential to hinder access to medicines, companies should waive
such exclusivity in all appropriate cases; while Guideline 31 identifies two occasions when the company should
waive data exclusivity, there will be other occasions when a waiver is appropriate as a way of enhancing access to
medicines for disadvantaged individuals, communities and populations. Access to medicines may be hindered when
a company applies for a patent for improvements to an existing medicine; Guideline 32 is designed to mitigate this
problem in low-income and middle-income countries. 
PATENTS AND LICENSING
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33 When formulating and implementing its access to medicines policy, the company should consider all the
arrangements at its disposal with a view to ensuring that its medicines are affordable to as many people as
possible. In keeping with Guideline 5, the company should give particular attention to ensuring its medi-
cines are accessible to disadvantaged individuals, communities and populations, including those living in
poverty and the very poorest in all markets. The arrangements should include, for example, differential
pricing between countries, differential pricing within countries, commercial voluntary licences, not-for-
profit voluntary licences, donation programmes, and Public Private Partnerships. 
34 The arrangements should take into account a country’s stage of economic development, as well as the dif-
ferential purchasing power of populations within a country. The same medicine, for example, may be priced
and packaged differently for the private and public sectors within the same country. 
35 The arrangements should extend to all medicines manufactured by the company, including those for non-
communicable conditions, such as heart disease and diabetes. 
36 The company should have a board-approved policy that fully conforms to the current World Health
Organisation Guidelines for Drug Donations.
37 The company should ensure that its discount and donation schemes and their delivery channels are:
i. as simple as possible e.g. the schemes should place the minimum administrative burden on the benefi-
ciary health system;
ii. as inclusive as possible e.g. the schemes should not be confined to delivery channels that, in practice,
exclude disadvantaged individuals and communities.
38 The company should disclose:
i. as much information as possible about its pricing and discounting arrangements; 
ii. the absolute quantity and value of its drug donations; 50 
iii. where possible, the number of beneficiary patients treated each year; 
iv. the amount of any tax benefit arising from its donations.
Commentary
While recognising they have a responsibility to enhance shareholder value, companies also have a human rights
responsibility to extend access to medicines for all, including disadvantaged individuals, communities and popula-
tions (Guideline 5). In this context, pricing has a critical role to play. Lower prices do not necessarily mean lower
profits. Sometimes the goal of enhancing access to medicines coincides with commercial interests. There are
numerous arrangements that may reduce prices and increase sales, some of which are mentioned in Guidelines 33
and 34. Because the lives and health of millions are at stake, companies must approach such arrangements with
urgency, creativity and boldness. They cannot act alone: here is another example of the shared responsibility
emphasised in the Preamble. Inventive arrangements should neither be confined to a company’s ‘flagship’ products
nor a narrow range of communicable diseases (Guideline 35). Although unsustainable in the long-term, a carefully
constructed donation programme may extend access (Guidelines 36-37). Guidelines have already emphasised, in
general terms, the central importance of transparency in relation to access to medicines (Guidelines 6-8); Guideline
38 applies this general principle of transparency to the specific context of pricing, discounting and donations.
PRICING, DISCOUNTING AND DONATIONS
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39 The company should take effective measures to ensure that all information bearing upon the safety, 
efficacy, and possible side effects of a medicine are easily accessible to individuals so they can take
informed decisions about its possible use.
40 The company should have a board-approved code of conduct and policy that fully conforms to the current
World Health Organisation Criteria for Medicinal Drug Promotion. In the context of this code and policy,
the board should receive regular reports on its promotion and marketing activities. 
41 The company should publicly disclose its promotional and marketing policies and activities, including costs.
Commentary
Guidelines have already emphasised, in general terms, the central importance of transparency in relation to access
to medicines (Guidelines 6-8); Guidelines 39-41 apply this general principle of transparency to the specific context
of ethical promotion and marketing. Promotion and marketing give rise to a wide-range of access to medicines
issues, such as advertising to health professionals and the general public, packaging and labelling, and information
for patients. Based on ethical considerations, the World Health Organisation Criteria for Medicinal Drug Promotion
provides authoritative guidance on these important matters (Guideline 40).
ETHICAL PROMOTION AND MARKETING
42 When participating in a Public Private Partnership, a company should continue to conform to these
Guidelines.
43 If a company joins a Public Private Partnership, it should disclose any interest it has in the Partnership’s
decisions and activities.
44 So far as these Guidelines bear upon the strategies, policies, programmes, projects and activities of Public
Private Partnerships, they shall apply equally to such Partnerships.
45 A company that joins a Public Private Partnership should take all reasonable steps to ensure the
Partnership fully conforms to these Guidelines. 
Commentary
Public Private Partnerships can make an important contribution to enhancing access to medicines. They are subject
to right-to-health considerations corresponding to those set out in these Guidelines. Where conflicts of interest
may arise, disclosure is important, consistent with the human rights requirements of transparency.
PUBLIC PRIVATE PARTNERSHIPS
46 So far as these Guidelines bear upon the strategies, policies, programmes, projects and activities of 
associations of pharmaceutical companies, they shall apply equally to all such associations. The Guidelines
on lobbying (Guidelines 17 and 26) and financial support (Guideline 18), for example, shall apply equally
to all associations of pharmaceutical companies. 
47 A company that is a member of an association of pharmaceutical companies should take all reasonable
steps to ensure the association fully conforms to these Guidelines. 
Commentary
A company has a responsibility to ensure that its professional associations are respectful of the right-to-health
considerations set out in these Guidelines, otherwise a company could use an association as a way of avoiding its
human rights responsibilities.
ASSOCIATIONS OF PHARMACEUTICAL COMPANIES
1  WHO, Medicines Strategy: Countries at the Core,
2004-2007, Geneva, WHO, 2004.
2  See Marks, S. (ed.), Health and Human Rights: Basic
International Documents, Harvard, HUP, 2006.
3  DFID, Increasing Access to Essential Medicines in the
Developing World, London, DFID, 2004.
4  WHO, Medicines Strategy, 2004-2007.
5  Ibid.
6  Millennium Development Goals, 2000, Target 17 of
Goal 8, available at www.undp.org/mdg/, accessed on
November, 8, 2007.
7  International Covenant on Economic, Social and
Cultural Rights (ICESCR), 1966, article 12 (2) (c) 
and (d).
8  For an excellent summary of relevant national
jurisprudence, see Hogerzeil, H. et al., “Is access to
essential medicines as part of the fulfilment of the
right to health enforceable through the courts?”,
Lancet, 2006. See also Commission on Human Rights
resolutions 2005/23, 2004/26 and 2003/29.
9  Report of the UN Special Rapporteur to the General
Assembly (A/61/338), 2006, para 92. 
10 UN Millennium Project, Public Choices, Private
Decisions: Sexual and Reproductive Health and
Millennium Development Goals, 2006.
11  WHO/UNFPA/PATH, Essential Medicines for
Reproductive Health: Guiding Principles for Their
Inclusion on National Medicines Lists, 2006. 
12 The Alan Guttmacher Institute, UNFPA, Adding It Up:
The Benefits of Investing in Sexual and Reproductive
Health Care, New York: AGI, UNFPA, 2004.
13 Glasier, A., Gülmezoglu, A., Schmid, G., et al., "Sexual
and Reproductive Health: a Matter of Life and
Death", The Lancet, October 2006.
14 The New York Call to Commitment: Linking HIV/AIDS
and Sexual and Reproductive Health, 2004, para 3.
15 WHO/UNFPA/IPPF/UNAIDS, Sexual and reproductive
health and HIV/AIDS, 2005.
16 IFPMA, Joining forces for change, pharmaceutical
industry in fight against HIV/AIDS, 2004.
17 WHO/UNAIDS/UNICEF, Towards Universal Access:
Scaling up Priority HIV/AIDS Interventions in the
Health Sector: Progress Report, 2008, p.82. 
ENDNOTES
22 Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines
Photograph © 2005
Galia Barkai, Courtesy
of Photoshare. An Indian
child, affected by the
Tsunami in a fishermen's
village near Madras, India
receives medication from
an Indian-Israeli medical
volunteer team.
ENDNOTES
Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines 23
18 Ibid, p. 87; see also WHO et al., Guidance on Global
Scale up of The Prevention of Mother-to-Child
Tranmission of HIV, 2007.
19 Ibid.  
20 See, Sexual and reproductive health and HIV/AIDS,
2005.
21 OHCHR/UNAIDS, International Guidelines on
HIV/AIDS and Human Rights, 2002.
22 UN Millennium Project, Prescription for Healthy
Development: Increasing Access to Medicines, Report
of the Task Force on HIV/AIDS, Malaria, TB, and
Access to Essential Medicines, 2005. 
23 Pharmaceutical Shareowners Group, The Public
Health Crisis in Emerging Markets, 2004.
24 Schiffman, M., Kjaer, L., "History of Anogenital
Human Papillomavirus Infection and Neoplasia",
Journal of the National Cancer Institute 2003;31:
pp.14-19.
25 Jansen, K., Shaw, A., "Human Papillomavirus Vaccines
and Prevention of Cervical Cancer", Annual Review of
Medicine, 2004, vol. 55, pp. 319-331.
26 Vizcaino, A., Morena, V., Bosch, F., et al.,
"International Trends in the Incidence of Cervical
Cancer: II squamous-cell carcinoma", International
Journal of Cancer, 2000, vol. 86, pp. 429-35.
27 Bosch, X., Harper, D., "Prevention strategies of cervi-
cal cancer in the HPV era", Gynaecologic Oncology,
2006, pp. 21-24.
28 Gostin, L., DeAngelis, C., "Mandatory HPV
Vaccination: Public Health versus Private Wealth",
JAMA, 2007, p.1921.
29 WHO, Cervical cancer, human papillomavirus and
HPV vaccines, 2007.
30 WHO, Human Papillomavirus and HPV Vaccines,
2007.
31 Ibid.
32 Dailard, C., "The Public Health Promise and Pitfalls 
of the World's First Cervical Cancer Vaccine",
Guttmacher Policy Review, 2006, pp. 6-9.
33 UNFPA, WHO, Sexual and Reproductive Health of
Women Living with HIV/AIDS, 2006.   
34 Vamos, C., et al., "The HPV Vaccine: Framing the
Arguments FOR and AGAINST Mandatory Vaccination
of All Middle School Girls", Journal of School Health,
vol 78, 2008, pp.302-209.  
35 Reports of the Special Rapporteur on the right to the
highest attainable standard of health on his mission
to Peru, 2005, E/CN.4/2005/51/Add.3 and Uganda,
2006, E/CN.4/2006/48/Add.2.
36 E/CN.4/2004/49/Add.1.
37 US-Peru trade negotiations: Special Rapporteur on
right to health reminds parties of human rights obli-
gations, UN press release, 5 July 2004; US-Peru free
trade pact: Special Rapporteur on right to health
reminds parties of human rights obligations, UN
press release, 13 July 2005.
38 Hunt, P., et al., "Neglected Diseases: A Human Rights
Analysis", WHO/TDR, Special Topics No.6, 2007.
39 A/HRC/7/11/Add.2.
40 See, in particular, A/61/338. 
41 CESCR, general comment 14, paragraph 42.
42 A/61/338.
43 Ibid.
44 Ibid.
45 “A Guide for Integrating Human Rights into Business
Management” available at http://www.blihr.org/.
46 “(I)t is inconceivable that some human rights do not
place legal obligations on business enterprises”,
A/61/338, paragraph 93.
47 Counterfeit drugs (medicines) are defined by the
World Health Organisation in FAQ’s on Counterfeit
Drugs, 2008.  
48 UNICEF, UNDP, World Bank, World Health
Organisation Special Programme for Research and
Training in Tropical Diseases.
49 Moran, M., et al., The New Landscape of Neglected
Disease Drug Development, The Wellcome Trust,
2005.
50 ‘Value’ as defined in Guideline 11, World Health
Organisation Guidelines for Drug Donations.
Human Rights Centre, University of Essex  
Colchester, Essex, CO4 3SQ, UK  
Tel +44 (0)1206 872558 Email hrc@essex.ac.uk 
Web www2.essex.ac.uk/human_rights_centre/
